Wegovy is genuinely good for your heart, and the evidence is strong enough that the FDA took an unusual step. In March 2024, the agency approved Wegovy specifically to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have cardiovascular disease and either obesity or overweight. That makes it the first weight-loss medication ever approved for this purpose.
What the Heart Data Actually Shows
The FDA’s approval was based on a large clinical trial called SELECT, which enrolled over 17,000 adults with established heart disease and a BMI of 27 or higher. These participants did not have diabetes. The trial tracked major cardiovascular events, including heart attacks, strokes, and deaths from cardiovascular causes, and found that Wegovy reduced the risk of these events by 20% compared to placebo.
That 20% reduction is meaningful. To put it in perspective, statins, which are considered one of the most successful cardiovascular drugs ever developed, typically reduce major events by about 25% to 30%. Wegovy isn’t far behind, and it works through a different set of mechanisms, meaning it may offer protection on top of what existing heart medications already provide.
How Wegovy Protects the Heart
The cardiovascular benefits go beyond simply losing weight, which surprised many researchers. Wegovy reduces C-reactive protein and other markers of inflammation throughout the body, and it does this independently of how much weight a person loses. Chronic inflammation is a major driver of plaque buildup in arteries, so dampening that process helps protect blood vessels over time.
Wegovy also directly improves the structure and function of the heart itself. In substudies from the clinical trial program, researchers found that people taking semaglutide had less enlargement of the left atrium (the upper chamber that often stretches in heart disease) and better relaxation of the left ventricle (the main pumping chamber). The right side of the heart showed improvements too. Some of these changes tracked with weight loss, but the improvements in how well the heart relaxes and the right ventricle’s size occurred even after accounting for weight, suggesting the drug has direct cardiac effects.
Benefits for Heart Failure
One of the more striking findings involves a specific type of heart failure called heart failure with preserved ejection fraction, or HFpEF. This is the most common form of heart failure in people with obesity, and until recently, treatment options were limited. In dedicated trials, people taking semaglutide reported substantially better quality of life, with symptom scores improving by about 7.5 points more than placebo on a standardized scale. That improvement was consistent in both men and women.
Beyond feeling better, participants also walked farther on a six-minute walking test, a standard measure of functional capacity in heart failure. For someone who struggles to walk across a parking lot or climb stairs, that kind of improvement translates directly into daily life. The proportions of patients who hit clinically meaningful improvement thresholds (5, 10, 15, and even 20 points on the symptom scale) were consistently higher with semaglutide regardless of sex.
Effects on Blood Pressure and Cholesterol
Wegovy lowers systolic blood pressure, the top number, which is one of the strongest predictors of heart attack and stroke risk. It also improves cholesterol profiles, with reductions in triglycerides and LDL cholesterol. These changes happen alongside weight loss, but they contribute meaningfully to the overall cardiovascular picture. For someone already on blood pressure or cholesterol medication, these additional improvements can help close the gap between their current numbers and their targets.
One Concern: Heart Rate
Wegovy does increase resting heart rate in most people who take it. Clinical trials consistently showed this effect, and it’s worth knowing about because a chronically elevated heart rate can, in some cases, raise the risk of certain heart rhythm problems. For most people, this increase is modest and doesn’t cause symptoms. But if you already have an arrhythmia or are at risk for one, it’s something to discuss before starting treatment.
There’s another practical consideration: Wegovy slows stomach emptying, which is part of how it reduces appetite. That delay can affect how quickly your body absorbs other oral medications, including heart drugs like blood thinners or blood pressure pills. Timing adjustments may be needed to keep those medications working properly.
How Wegovy Compares to Other GLP-1 Drugs
Wegovy belongs to a class of drugs called GLP-1 receptor agonists, and it’s not the only one with cardiovascular evidence. Liraglutide and dulaglutide, both used for type 2 diabetes, have also demonstrated heart benefits in clinical trials and carry guideline recommendations for cardiovascular risk reduction. The key difference is that Wegovy is the first in this class approved specifically for heart protection in people without diabetes.
Tirzepatide (sold as Mounjaro and Zepbound) works on a similar pathway but adds a second hormone target. Its cardiovascular outcomes trial has been completed, and while the data is promising, the formal results and any potential heart-related FDA indication are still being evaluated. For now, Wegovy stands alone as the GLP-1 drug with an explicit cardiovascular approval for the non-diabetic population.
Medicare and Insurance Coverage
Cost has been a major barrier to Wegovy, but the cardiovascular approval opened a new door. Medicare Part D now covers Wegovy when it’s prescribed to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This is a significant change, because Medicare has historically excluded weight-loss drugs from coverage. The cardiovascular indication sidesteps that exclusion entirely.
To get coverage, your prescriber will need to document your cardiovascular diagnosis and complete the utilization management requirements set by your specific Part D plan. This typically means prior authorization paperwork confirming you meet the criteria. If your plan doesn’t list Wegovy on its formulary, the standard formulary exception process still applies. Private insurers have been slower and more variable in their coverage decisions, but the FDA-approved heart indication gives prescribers stronger footing when appealing denials.